Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Clinical Strategies to Improve Efficacy, Effectiveness, and Safety of Vaccination...
share announcement

Clinical Strategies to Improve Efficacy, Effectiveness, and Safety of Vaccination in Humans

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: 12 November 2024 | Viewed by 746

Special Issue Editor

Dr. Kay Choong See

E-Mail Website
Guest Editor
Division of Respiratory and Critical Care Medicine, Department of Medicine, National University Hospital, Singapore 119228, Singapore
Interests: respiratory infection; intensive care medicine; public health
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

I am pleased to invite you to contribute to an upcoming Special Issue, titled "Clinical Strategies to Improve Efficacy, Effectiveness, and Safety of Vaccination in Humans". Vaccination remains a cornerstone in preventing infectious diseases and is a key contributor to global health. In this context, advancing clinical strategies is crucial for enhancing the overall impact of vaccination programs.

The scientific foundation of this Special Issue lies in addressing current challenges and exploring innovative approaches to optimize vaccination outcomes. Embracing a broad scope, we welcome contributions involving, but not limited to, the following:

  1. Participants of all ages.
  2. Special populations as those with comorbid conditions and immunocompromised patients.
  3. The use of any human vaccine platform.
  4. Diverse research designs, including randomized trials, nonrandomized trials, quality improvement studies, case–control studies, systematic reviews, and narrative reviews.
  5. Clinical vaccine research and utilization under controlled or real-world settings.

I look forward to receiving your valuable contributions.

Dr. Kay Choong See
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • adenovirus vaccines
  • immunologic adjuvants
  • adult
  • communicable diseases
  • geriatrics
  • immunocompromised Host
  • mRNA vaccines
  • pediatrics
  • public health
  • attenuated vaccines
  • inactivated vaccines

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 4038 KiB  
Article
Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial
by Julie A. Ake, Kristopher Paolino, Jack N. Hutter, Susan Biggs Cicatelli, Leigh Anne Eller, Michael A. Eller, Margaret C. Costanzo, Dominic Paquin-Proulx, Merlin L. Robb, Chi L. Tran, Lalaine Anova, Linda L. Jagodzinski, Lucy A. Ward, Nicole Kilgore, Janice Rusnak, Callie Bounds, Christopher S. Badorrek, Jay W. Hooper, Steven A. Kwilas, Ine Ilsbroux, Dickson Nkafu Anumendem, Auguste Gaddah, Georgi Shukarev, Viki Bockstal, Kerstin Luhn, Macaya Douoguih and Cynthia Robinsonadd Show full author list remove Hide full author list
Vaccines 2024, 12(5), 497; https://doi.org/10.3390/vaccines12050497 - 4 May 2024
Viewed by 579
Abstract
The safety and immunogenicity of the two-dose Ebola vaccine regimen MVA-BN-Filo, Ad26.ZEBOV, 14 days apart, was evaluated in people without HIV (PWOH) and living with HIV (PLWH). In this observer-blind, placebo-controlled, phase 2 trial, healthy adults were randomized (4:1) to receive MVA-BN-Filo (dose [...] Read more.
The safety and immunogenicity of the two-dose Ebola vaccine regimen MVA-BN-Filo, Ad26.ZEBOV, 14 days apart, was evaluated in people without HIV (PWOH) and living with HIV (PLWH). In this observer-blind, placebo-controlled, phase 2 trial, healthy adults were randomized (4:1) to receive MVA-BN-Filo (dose 1) and Ad26.ZEBOV (dose 2), or two doses of saline/placebo, administered intramuscularly 14 days apart. The primary endpoints were safety (adverse events (AEs)) and immunogenicity (Ebola virus (EBOV) glycoprotein-specific binding antibody responses). Among 75 participants (n = 50 PWOH; n = 25 PLWH), 37% were female, the mean age was 44 years, and 56% were Black/African American. AEs were generally mild/moderate, with no vaccine-related serious AEs. At 21 days post-dose 2, EBOV glycoprotein-specific binding antibody responder rates were 100% among PWOH and 95% among PLWH; geometric mean antibody concentrations were 6286 EU/mL (n = 36) and 2005 EU/mL (n = 19), respectively. A total of 45 neutralizing and other functional antibody responses were frequently observed. Ebola-specific CD4+ and CD8+ T-cell responses were polyfunctional and durable to at least 12 months post-dose 2. The regimen was well tolerated and generated robust, durable immune responses in PWOH and PLWH. Findings support continued evaluation of accelerated vaccine schedules for rapid deployment in populations at immediate risk. Trial registration: NCT02598388 (submitted 14 November 2015). Full article
(This article belongs to the Special Issue Clinical Strategies to Improve Efficacy, Effectiveness, and Safety of Vaccination in Humans)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop